Last reviewed · How we verify
NCT04587388: LUPIAE
Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry
trial in Follicular Lymphoma in 500 participants. Currently enrolling.
22 May 2023
Quick facts
| Lead sponsor | European Hematology Association - Lymphoma Group |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 22 May 2019 |
| Primary completion | 22 May 2023 |
| Estimated completion | 22 May 2026 |
| Sites | 11 locations across Italy, Netherlands, Ukraine, Portugal, Croatia, Spain |
Conditions studied
- Follicular Lymphoma — all drugs for Follicular Lymphoma →
- Relapsed/Refractory Follicular Lymphoma — all drugs for Relapsed/Refractory Follicular Lymphoma →
Sponsor
European Hematology Association - Lymphoma Group
Who can join
18 and older, any sex, with Follicular Lymphoma or Relapsed/Refractory Follicular Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The optimal treatment strategy in patients with early progressive disease is not well known. In recent years, novel insights into the biology of Follicular Lymphoma (FL), and especially the role of the microenvironment, have resulted in the development of multiple novel treatment modalities. These new agents may ultimately improve the outlook for patients with FL with an unfavorable course, but for the development of the optimal therapeutic strategy, knowledge on the clinical and biological determinants of early refractory FL is needed.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Towards personalized medicine for refractory/relapsed follicular lymphoma patients: The Lupiae-Cantera study.
Dogliotti I, Tonino S, Conte L, Stepanishyna Y, et al · · 2025 · PMID 41069393 · DOI 10.1002/hem3.70230
Verify or expand the search:
- PubMed search for NCT04587388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Follicular Lymphoma
Currently open trials in the same condition.
- NCT07128641 — Odronextamab in Low Tumor Volume Advanced FL · Phase 2 · recruiting
- NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
- NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
- NCT07126678 — Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma · NA · recruiting
- NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04587388 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by European Hematology Association - Lymphoma Group
- Last refreshed: 14 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04587388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing